Population
Patients with cardiovascular diseases including systolic heart failure, diastolic heart failure, and…
Design
Review
Authors
Loading...
May inform beta-blocker selection in systolic HF; leaves open mechanistic questions on rate reduction in CAD.
Beta-blockers are a heterogeneous class of drugs whose specific receptor selectivity and vasodilating properties dictate their clinical utility and metabolic side effect profiles in various cardiovascular diseases.
Gorré et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: